Navigation Links
DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery
Date:10/14/2009

Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, today announced it will feature the latest developments in its advanced DuraHeart™ Left-Ventricular Assist System at the 23rd Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS), Vienna, Austria, October 17-21.

Ann Arbor, Mich. (PRWEB) -- Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, today announced it will feature the latest developments in its advanced DuraHeart™ Left-Ventricular Assist System at the 23rd Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS), Vienna, Austria, October 17-21.

The DuraHeart LVAS is a third-generation mechanical circulatory support device designed for long-term patient use. The DuraHeart LVAS incorporates a centrifugal flow rotary pump with an active magnetically levitated impeller featuring three position sensors and magnetic coils to optimize blood flow, while minimizing device wear and tear.

The DuraHeart LVAS carries a CE Mark and is commercially available in Europe. It is currently being evaluated in the DuraHeart Pivotal U.S. Trial for Bridge to Transplant. The 140-patient U.S. trial will involve up to 40 centers. The device has also completed its clinical trial enrollment for its future submission for review and approval in Japan.

"The DuraHeart LVAS is unique when compared to second-generation devices which use mechanical bearings within the blood chamber to provide circulatory support," said William Pinon, President and CEO, Terumo Heart. "Our technology delivers magnetic levitation for a friction-free environment that ensures long-term durability. In fact, to date our data set includes more than 78 combined patient years with some of our earliest patients remaining on the device for over four years."

The DuraHeart LVAS offers competitive advantages over existing technology. The impeller's magnetic levitation eliminates premature friction wear and allows a wide gap between blood contact surface areas, enabling blood to flow through the pump unimpeded in a smooth non-turbulent fashion. In addition, a hydrodynamic failsafe, that enables the pump to continue working under conditions that might cause other devices to fail, provides reassurance to patients and physicians.

"We are excited to bring DuraHeart to our customers during this important meeting," said Pinon. "As we expand our clinical experience worldwide and prepare to engage new centers in new markets, feedback from our customers will ensure we stay on track and offer the best treatment option."

The EACTS meeting offers Terumo Heart an excellent opportunity to showcase its unique technology and gather valuable feedback from cardiac surgeon customers in the field of Heart Failure surgery. To learn more about the DuraHeart LVAS program, please visit Terumo Heart representatives at exhibit booth number 32 during the meeting.

About Heart Failure
More than 22 million people suffer from heart failure worldwide with approximately one million new patients diagnosed annually. In the setting of an aging global population, heart failure is the number one reason for hospitalization. The most severely ill patients need heart transplants in order to recover. More than 8,000 people worldwide are on the list of eligible candidates for heart transplants annually, but less than 3,000 will receive a transplant each year. A large number of people who suffer from severe heart failure do not qualify for transplantation due to other health issues. An alternative for these patients is access to artificial mechanical assist devices. Left Ventricular Assist Systems are a type of mechanical circulatory device specifically designed to improve the quality of life of the patients waiting for donor hearts, as well as those who are ineligible for a heart transplant.

About Terumo Heart, Inc.
Terumo Heart, Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for heart failure patients. Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products. DuraHeart is limited to investigational use only in the United States, and is CE marked in Europe. For more information visit www.terumoheart.com.

###

Read the full story at http://www.prweb.com/releases/2009/10/prweb3042904.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Terumo Heart, Inc.'s DuraHeart™ Left-Ventricular Assist System Featured at Future of Health Technology Summit
2. AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
3. Breaking Study: Masimo Pleth Variability Index (PVI) Shown Effective in Noninvasive Detection of Changes in Ventricular Preload and Fluid Volume
4. URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device
5. Improving survival rates among users of left ventricular assist devices
6. First Implant of DuraHeart(TM) Left Ventricular Assist System (LVAS) in Japanese Clinical Trial
7. Heart Failure Patients With Normal Left Ventricular Ejection Fraction Dont Benefit From Treatment With Angiotensin II Receptor Blocker
8. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
9. Hahnemann University Hospital Awarded Certification From the Joint Commission for Ventricular Assist Devices
10. Expert consensus on catheter ablation of ventricular arrhythmias
11. MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral Regurgitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... ... May 30, 2016 , ... ... Shaolin warrior 8-day-8 and 8-night special intensive summer training camp starts on June ... summer camp offers families and children a fun and unique experience with an ...
(Date:5/29/2016)... ... May 29, 2016 , ... Whole Health Supply is ... new KlipPro KP-240L clipper is available to the public. This is an unusual clipper ... wider than the average clipper. , Everything about this product is concentrated on ease ...
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can be ... a preset onto their media," said Christina Austin - CEO of Pixel Film Studios. ... quickly and easily add stylish color grades to their footage. A LUT is a ...
(Date:5/28/2016)... ... , ... In a part of the city where’s it’s easy to spot the neon lights ... is hoping to attract diners with a taste for real food. , On May ... to Cornerstone Grill, an urban casual restaurant focusing on dishes made by hand with wholesome, ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue ... Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields ... Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... May 27, 2016 Amarantus BioScience Holdings, ... developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced ... presenting at two upcoming investor conferences: SeeThru Equity ... Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand Hyatt Hotel, ...
(Date:5/26/2016)... , May 26, 2016   ... software and analytics, network solutions and technology-enabled ... announced it entered into a strategic channel ... of outpatient software solutions and revenue cycle ... specialty hospitals and rehabilitation clinics to optimize ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, ... QGEN ; Frankfurt Prime Standard: QIA) today announced that the ... Therawis Diagnostics GmbH to develop and commercialize predictive assays in ... PITX2 as a marker to predict effectiveness of anthracycline treatment ... "We are pleased to partner with Therawis, which developed ...
Breaking Medicine Technology: